Integer (NYSE:ITGR) Reaches New 1-Year High – Time to Buy?

Integer Holdings Co. (NYSE:ITGR) hit a new 52-week high on Tuesday . The company traded as high as $144.22 and last traded at $143.22, with a volume of 5118 shares changing hands. The stock had previously closed at $141.00.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Citigroup increased their price objective on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Bank of America lifted their target price on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Truist Financial increased their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, KeyCorp boosted their price objective on Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.44.

Integer Stock Performance

The company has a 50 day moving average price of $136.56 and a 200-day moving average price of $129.05. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.78 billion, a P/E ratio of 43.96, a PEG ratio of 1.80 and a beta of 1.12.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The firm had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. Integer’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $1.27 EPS. Equities analysts expect that Integer Holdings Co. will post 5.33 EPS for the current fiscal year.

Institutional Trading of Integer

Hedge funds and other institutional investors have recently modified their holdings of the company. Exchange Traded Concepts LLC grew its stake in shares of Integer by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,800 shares of the medical equipment provider’s stock worth $769,000 after purchasing an additional 145 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Integer by 2.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 9,865 shares of the medical equipment provider’s stock worth $1,307,000 after buying an additional 197 shares in the last quarter. Heritage Family Offices LLP grew its position in Integer by 6.9% in the fourth quarter. Heritage Family Offices LLP now owns 3,033 shares of the medical equipment provider’s stock worth $402,000 after buying an additional 197 shares during the last quarter. Contravisory Investment Management Inc. increased its holdings in shares of Integer by 210.8% in the fourth quarter. Contravisory Investment Management Inc. now owns 693 shares of the medical equipment provider’s stock valued at $92,000 after buying an additional 470 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its stake in shares of Integer by 26.0% during the 4th quarter. Park Avenue Securities LLC now owns 4,710 shares of the medical equipment provider’s stock worth $624,000 after acquiring an additional 972 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.